Transcranial Direct Stimulation for Persistent Fatigue Treatment Post-COVID-19 (STIMULATECOVID)
Modulation of Post-COVID-19 Fatigue Using Transcranial Direct Current Stimulation. Transcranial Direct Stimulation for Persistent Fatigue Treatment Post-COVID-19
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Madrid, Spain, 28040
- Hospital Clínico San Carlos.
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of COVID-19 with PCR-confirmation.
- Fatigue linked to COVID-19
- No diagnosis of neurological, psychiatric or medical disorder with potential impact on fatigue.
Exclusion Criteria:
- Stroke before COVID-19
- History of traumatic brain lesion or central nervous system infection previous to COVID-19
- Radiotherapy or chemotherapy for cancer
- Severe sensorial deficits
- Drugs or uncontrolled medical disorder with potential impact on fatigue.
- History of abuse of alcohol or other toxics.
- Any contraindication for tDCS (metallic implants, brain devices, pacemakers, head injuries).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Active tDCS
Transcranial current direct stimulation.
8 days.
|
Eight sessions of transcranial current direct stimulation
|
|
Sham Comparator: Sham tDCS
Sham transcranial current direct stimulation.
8 days.
|
Eight sessions of transcranial current direct stimulation (sham)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Fatigue
Time Frame: 2 weeks
|
Modified Fatigue Impact Scale (MFIS)
|
2 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in cognition
Time Frame: 2 weeks
|
Stroop Test
|
2 weeks
|
|
Change in depressive symptoms
Time Frame: 2 weeks
|
Beck Depression Inventory II
|
2 weeks
|
|
Change in quality of life
Time Frame: 2 weeks
|
EuroQuol-5D
|
2 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 22-120
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.